

**RNS**  
**AIM: FIPP**  
**25 September 2025**

**Frontier IP Group Plc**  
**("Frontier IP" or the "Group")**

**Announcement of Board Change**

Frontier IP, a specialist in commercialising intellectual property, today announces that Matthew White (Chief Commercialisation Officer) has decided to leave the Group to pursue an opportunity as Chief Executive Officer of a Cambridge based early-stage medical devices company.

It is currently intended that Mr White will remain with the Company as Chief Commercialisation Officer and an Executive Director of the Company until the end of his six month notice period on 24 March 2026.

The Group is in discussions about a successor and a further update will be issued when appropriate.

**Frontier IP Chief Executive Officer Neil Crabb said:** *"I am sorry Matt is leaving the Group. His departure is wholly amicable. In the seven years he has been our Chief Commercialisation Officer, he has played an invaluable role in the progress made by Frontier IP and our portfolio companies. I would like to wish him all the best in the exciting role he is to fulfil. I am sure he will be a great success."*

**Frontier IP Chief Commercialisation Officer Matthew White said:** *"It has been a privilege to be involved in the development of the Frontier IP portfolio over the last seven years. I look forward to the continued success of the portfolio and Frontier IP's growing engagement in the Cambridge deeptech ecosystem."*

**ENQUIRIES**

**Frontier IP Group Plc** T: 020 7332 2338

Neil Crabb, Chief Executive neil@frontierip.co.uk  
M: 07464 546 025

Andrew Johnson,  
Communications &  
Investor Relations

Company website:  
[www.frontierip.co.uk](http://www.frontierip.co.uk)

**Allenby Capital Limited**  
**(Nominated Adviser)** T: 0203 328 5656

Nick Athanas / Daniel Dearden-Williams T: 0207 496 3000

**Singer Capital Markets (Broker)**

Charles Leish

Charles Leigh-  
Pemberton / James  
Fischer

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOALIMPTMTMTBBA